Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Rolf Larsson

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Anatomy

Chemicals & Drugs

Procedures

Physiology

Concepts & Ideas

Drug Dose-Response Relationship

Disorders

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Laryea Daniel; Isaksson Anders; Wright Colin W; Larsson Rolf; Nygren Peter
Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients.
Berndtsson Maria; Beaujouin Melanie; Rickardson Linda; Havelka Aleksandra Mandic; Larsson Rolf; Westman Jacob; Liaudet-Coopman Emmanuelle; Linder Stig
Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system.
Lönnerholm Gudmar; Thörn Ingrid; Sundström Christer; Frost Britt-Marie; Abrahamsson Jonas; Behrendtz Mikael; Heldrup Jesper; Jacobsson Stefan; Li Aihong; Olofsson Tor; Porwit Anna; Söderhäll Stefan; Larsson Rolf; Forestier Erik
In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Rolf Larsson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Laryea Daniel; Isaksson Anders; Wright Colin W; Larsson Rolf; Nygren Peter
Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients.
Investigational new drugs 2009;27(5):402-11.
2009: Berndtsson Maria; Beaujouin Melanie; Rickardson Linda; Havelka Aleksandra Mandic; Larsson Rolf; Westman Jacob; Liaudet-Coopman Emmanuelle; Linder Stig
Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system.
International journal of cancer. Journal international du cancer 2009;124(6):1463-9.
2009: Lönnerholm Gudmar; Thörn Ingrid; Sundström Christer; Frost Britt-Marie; Abrahamsson Jonas; Behrendtz Mikael; Heldrup Jesper; Jacobsson Stefan; Li Aihong; Olofsson Tor; Porwit Anna; Söderhäll Stefan; Larsson Rolf; Forestier Erik
In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
Leukemia research 2009;33(1):46-53.
2009: Fayad Walid; Fryknäs Mårten; Brnjic Slavica; Olofsson Maria Hägg; Larsson Rolf; Linder Stig
Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.
PloS one 2009;4(10):e7238.
2009: Wiberg Kristina; Carlson Kristina; Aleskog Anna; Larsson Rolf; Nygren Peter; Lindhagen Elin
In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.
Medical oncology (Northwood, London, England) 2009;26(2):193-201.
2008: Thorslund Sara; Larsson Rolf; Bergquist Jonas; Nikolajeff Fredrik; Sanchez Javier
A PDMS-based disposable microfluidic sensor for CD4+ lymphocyte counting.
Biomedical microdevices 2008;10(6):851-7.
2008: Lindhagen Elin; Eriksson Anna; Wickström Malin; Danielsson Katarina; Grundmark Birgitta; Henriksson Roger; Nygren Peter; Aleskog Anna; Larsson Rolf; Höglund Martin
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.
European journal of haematology 2008;81(5):344-53.
2008: Ahlin Gustav; Karlsson Johan; Pedersen Jenny M; Gustavsson Lena; Larsson Rolf; Matsson Pär; Norinder Ulf; Bergström Christel A S; Artursson Per
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Journal of medicinal chemistry 2008;51(19):5932-42.
2008: Cabric Sanja; Eich Torsten; Sanchez Javier; Nilsson Bo; Korsgren Olle; Larsson Rolf
A new method for incorporating functional heparin onto the surface of islets of Langerhans.
Tissue engineering. Part C, Methods 2008;14(2):141-7.
2008: Wickström Malin; Haglund Caroline; Lindman Henrik; Nygren Peter; Larsson Rolf; Gullbo Joachim
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.
Investigational new drugs 2008;26(3):195-204.
2008: Lindhagen Elin; Nygren Peter; Larsson Rolf
The fluorometric microculture cytotoxicity assay.
Nature protocols 2008;3(8):1364-9.
2008: Sanchez J; Elgue G; Larsson R; Nilsson B; Olsson P
Surface-adsorbed fibrinogen and fibrin may activate the contact activation system.
Thrombosis research 2008;122(2):257-63.
2007: Wickström Malin; Johnsen John Inge; Ponthan Frida; Segerström Lova; Sveinbjörnsson Baldur; Lindskog Magnus; Lövborg Henrik; Viktorsson Kristina; Lewensohn Rolf; Kogner Per; Larsson Rolf; Gullbo Joachim
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
Molecular cancer therapeutics 2007;6(9):2409-17.
2007: Hassan S B; Haglund C; Aleskog A; Larsson R; Lindhagen E
Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity.
Toxicology in vitro : an international journal published in association with BIBRA 2007;21(6):1174-81.
2007: Lindhagen Elin; Nissle Sara; Leoni Lorenzo; Elliott Gary; Chao Qi; Larsson Rolf; Aleskog Anna
R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells.
Cancer chemotherapy and pharmacology 2007;60(4):545-53.
2007: Quartino Angelica; Karlsson Mats O; Freijs Agneta; Jonsson Niclas; Nygren Peter; Kristensen Jörgen; Lindhagen Elin; Larsson Rolf
Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia.
Journal of clinical pharmacology 2007;47(8):1014-21.
2007: Cabric Sanja; Sanchez Javier; Lundgren Torbjörn; Foss Aksel; Felldin Marie; Källen Ragnar; Salmela Kaija; Tibell Annika; Tufveson Gunnar; Larsson Rolf; Korsgren Olle; Nilsson Bo
Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation.
Diabetes 2007;56(8):2008-15.
2007: Lindhagen Elin; Rickardson Linda; Elliott Gary; Leoni Lorenzo; Nygren Peter; Larsson Rolf; Aleskog Anna
Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.
Investigational new drugs 2007;25(4):297-303.
2007: Rickardson Linda; Wickström Malin; Larsson Rolf; Lövborg Henrik
Image-based screening for the identification of novel proteasome inhibitors.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening 2007;12(2):203-10.
2007: Andersson C R; Fryknäs M; Rickardson L; Larsson R; Isaksson A; Gustafsson M G
In vitro drug sensitivity-gene expression correlations involve a tissue of origin dependency.
Journal of chemical information and modeling 2007;47(1):239-48.
2007: Fryknäs Mårten; Dhar Sumeer; Oberg Fredrik; Rickardson Linda; Rydåker Maria; Göransson Hanna; Gustafsson Mats; Pettersson Ulf; Nygren Peter; Larsson Rolf; Isaksson Anders
STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines.
International journal of cancer. Journal international du cancer 2007;120(1):189-95.
2007: Wickström Malin; Danielsson Katarina; Rickardson Linda; Gullbo Joachim; Nygren Peter; Isaksson Anders; Larsson Rolf; Lövborg Henrik
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.
Biochemical pharmacology 2007;73(1):25-33.
2007: Milani Lili; Gupta Manu; Andersen Malin; Dhar Sumeer; Fryknäs Mårten; Isaksson Anders; Larsson Rolf; Syvänen Ann-Christine
Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells.
Nucleic acids research 2007;35(5):e34.
2006: Rickardson Linda; Fryknäs Mårten; Haglund Caroline; Lövborg Henrik; Nygren Peter; Gustafsson Mats G; Isaksson Anders; Larsson Rolf
Screening of an annotated compound library for drug activity in a resistant myeloma cell line.
Cancer chemotherapy and pharmacology 2006;58(6):749-58.
2006: Hassan Saadia B; Lövborg Henrik; Lindhagen Elin; Karlsson Mats O; Larsson Rolf
CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome.
Anticancer research 2006;26(6B):4431-6.
2006: Larsson Dhana E; Lövborg Henrik; Rickardson Linda; Larsson Rolf; Oberg Kjell; Granberg Dan
Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines.
Anticancer research 2006;26(6B):4125-9.
2006: Fryknäs Mårten; Rickardson Linda; Wickström Malin; Dhar Sumeer; Lövborg Henrik; Gullbo Joachim; Nygren Peter; Gustafsson Mats G; Isaksson Anders; Larsson Rolf
Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening 2006;11(5):457-68.
2006: Olsson-Strömberg Ulla; Aleskog Anna; Björnberg Anneli; Höglund Martin; Simonsson Bengt; Bengtsson Mats; Barbany Gisela; Larsson Rolf; Lindhagen Elin
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Anti-cancer drugs 2006;17(6):631-9.
2006: Kristensen E M E; Larsson R; Sánchez J; Rensmo H; Gelius U; Siegbahn H
Heparin coating durability on artificial heart valves studied by XPS and antithrombin binding capacity.
Colloids and surfaces. B, Biointerfaces 2006;49(1):1-7.
2006: Lövborg Henrik; Oberg Fredrik; Rickardson Linda; Gullbo Joachim; Nygren Peter; Larsson Rolf
Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram.
International journal of cancer. Journal international du cancer 2006;118(6):1577-80.
2005: Thorslund Sara; Sanchez Javier; Larsson Rolf; Nikolajeff Fredrik; Bergquist Jonas
Bioactive heparin immobilized onto microfluidic channels in poly(dimethylsiloxane) results in hydrophilic surface properties.
Colloids and surfaces. B, Biointerfaces 2005;46(4):240-7.
2005: Thorslund Sara; Sanchez Javier; Larsson Rolf; Nikolajeff Fredrik; Bergquist Jonas
Functionality and stability of heparin immobilized onto poly(dimethylsiloxane).
Colloids and surfaces. B, Biointerfaces 2005;45(2):76-81.
2005: Aleskog Anna; Höglund Martin; Pettersson Jenny; Hermansson Monica; Larsson Rolf; Lindhagen Elin
In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia.
Leukemia research 2005;29(9):1079-81.
2005: Rickardson L; Fryknäs M; Dhar S; Lövborg H; Gullbo J; Rydåker M; Nygren P; Gustafsson M G; Larsson R; Isaksson A
Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles.
British journal of cancer 2005;93(4):483-92.
2005: Hallböök Helene; Barbany Gisela; Aleskog Anna; Björnberg Annelie; Larsson Rolf; Sundström Christer; Lindhagen Elin
In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia.
Anti-cancer drugs 2005;16(6):631-4.
2005: Lövborg Henrik; Gullbo Joachim; Larsson Rolf
Screening for apoptosis--classical and emerging techniques.
Anti-cancer drugs 2005;16(6):593-9.
2005: Friberg Lena E; Hassan Saadia B; Lindhagen Elin; Larsson Rolf; Karlsson Mats O
Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;25(1):163-73.
2005: Johnell M; Larsson R; Siegbahn A
The influence of different heparin surface concentrations and antithrombin-binding capacity on inflammation and coagulation.
Biomaterials 2005;26(14):1731-9.
2005: Aleskog Anna; Larsson Rolf; Höglund Martin; Kristensen Jörgen; Nygren Peter; Lindhagen Elin
In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia.
Anti-cancer drugs 2005;16(3):277-83.
2005: Hassan Saadia; Dhar Sumeer; Sandström Marie; Arsenau Dzmitry; Budnikova Marina; Lokot Igor; Lobanov Nikolai; Karlsson Mats O; Larsson Rolf; Lindhagen Elin
Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo.
Cancer chemotherapy and pharmacology 2005;55(1):47-54.
2004: Aleskog Anna; Tobin Gerard; Laurell Anna; Thunberg Ulf; Lindhagen Elin; Roos Göran; Nilsson Kenneth; Nygren Peter; Sundström Christer; Höglund Martin; Larsson Rolf; Rosenquist Richard
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
European journal of haematology 2004;73(6):407-11.
2004: Gullbo Joachim; Lindhagen Elin; Bashir-Hassan Saadia; Tullberg Marcus; Ehrsson Hans; Lewensohn Rolf; Nygren Peter; De La Torre Manuel; Luthman Kristina; Larsson Rolf
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
Investigational new drugs 2004;22(4):411-20.
2004: Lövborg Henrik; Nygren Peter; Larsson Rolf
Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828.
Molecular cancer therapeutics 2004;3(5):521-6.
2004: Svangård Erika; Göransson Ulf; Hocaoglu Zozan; Gullbo Joachim; Larsson Rolf; Claeson Per; Bohlin Lars
Cytotoxic cyclotides from Viola tricolor.
Journal of natural products 2004;67(2):144-7.
2004: Hovstadius Peter; Lindhagen Elin; Hassan Sadia; Nilsson Kenneth; Jernberg-Wiklund Helena; Nygren Peter; Binderup Lise; Larsson Rolf
Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines.
Anti-cancer drugs 2004;15(1):63-70.
2004: Gullbo Joachim; Lövborg Henrik; Dhar Sumeer; Lukinius Agneta; Oberg Fredrik; Nilsson Kenneth; Björkling Fredrik; Binderup Lise; Nygren Peter; Larsson Rolf
Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.
Anti-cancer drugs 2004;15(1):45-54.
2003: Gullbo Joachim; Wallinder Charlotta; Tullberg Marcus; Lövborg Henrik; Ehrsson Hans; Lewensohn Rolf; Nygren Peter; Luthman Kristina; Larsson Rolf
Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.
Molecular cancer therapeutics 2003;2(12):1331-9.
2003: Andersson Jonas; Sanchez Javier; Ekdahl Kristina Nilsson; Elgue Graciela; Nilsson Bo; Larsson Rolf
Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro.
Journal of biomedical materials research. Part A 2003;67(2):458-66.
2003: Kristensen E M E; Rensmo H; Larsson R; Siegbahn H
Characterization of heparin surfaces using photoelectron spectroscopy and quartz crystal microbalance.
Biomaterials 2003;24(23):4153-9.
2003: Gullbo Joachim; Dhar Sumeer; Luthman Kristina; Ehrsson Hans; Lewensohn Rolf; Nygren Peter; Larsson Rolf
Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
Anti-cancer drugs 2003;14(8):617-24.
2003: Gullbo Joachim; Wickström Malin; Tullberg Marcus; Ehrsson Hans; Lewensohn Rolf; Nygren Peter; Luthman Kristina; Larsson Rolf
Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.
Journal of drug targeting 2003;11(6):355-63.
2003: Henningsson A; Sparreboom A; Sandström M; Freijs A; Larsson R; Bergh J; Nygren P; Karlsson M O
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1105-14.
2003: Johansson S; Gullbo J; Lindholm P; Ek B; Thunberg E; Samuelsson G; Larsson R; Bohlin L; Claeson P
Small, novel proteins from the mistletoe Phoradendron tomentosum exhibit highly selective cytotoxicity to human breast cancer cells.
Cellular and molecular life sciences : CMLS 2003;60(1):165-75.
2003: Gullbo Joachim; Tullberg Marcus; Våbenø Jon; Ehrsson Hans; Lewensohn Rolf; Nygren Peter; Larsson Rolf; Luthman Kristina
Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.
Oncology research 2003;14(3):113-32.
2002: Gullbo Joachim; Arsenau Dzimitry; Grundmark Birgitta; Alvfors Carina; Larsson Rolf; Lindhagen Elin
Cytotoxic activity of a new lipid formulation of doxorubicin in cell lines and primary tumor cells.
Anticancer research 2002;22(6C):4191-8.
2002: Martinsson P; Ekelund S; Nygren P; Larsson R
The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro--from cytotoxic synergy to complete inhibition of apoptosis.
British journal of pharmacology 2002;137(4):568-73.
2002: Hovstadius Peter; Larsson Rolf; Jonsson Elin; Skov Torsten; Kissmeyer Anne-Marie; Krasilnikoff Klaus; Bergh Jonas; Karlsson Mats O; Lönnebo Anna; Ahlgren Johan
A Phase I study of CHS 828 in patients with solid tumor malignancy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2843-50.
2002: Ekelund Sara; Persson Ingrid; Larsson Rolf; Nygren Peter
Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients.
Chemotherapy 2002;48(4):196-204.
2002: Li Shi-Sheng; Gullbo Joachim; Lindholm Petra; Larsson Rolf; Thunberg Eva; Samuelsson Gunnar; Bohlin Lars; Claeson Per
Ligatoxin B, a new cytotoxic protein with a novel helix-turn-helix DNA-binding domain from the mistletoe Phoradendron liga.
The Biochemical journal 2002;366(Pt 2):405-13.
2002: Lindholm Petra; Gullbo Joachim; Claeson Per; Göransson Ulf; Johansson Senia; Backlund Anders; Larsson Rolf; Bohlin Lars
Selective cytotoxicity evaluation in anticancer drug screening of fractionated plant extracts.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening 2002;7(4):333-40.
2002: Johnell Matilda; Elgue Graciela; Larsson Rolf; Larsson Anders; Thelin Stefan; Siegbahn Agneta
Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface.
The Journal of thoracic and cardiovascular surgery 2002;124(2):321-32.
2002: Lövborg Henrik; Wojciechowski Jacek; Larsson Rolf; Wesierska-Gadek Józefa
Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1.
Cancer research 2002;62(15):4206-11.
2002: Ekelund Sara; Larsson Rolf; Nygren Peter
Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells.
Anticancer research 2002;22(4):2269-74.
2002: Aleskog Anna; Jonsson Elin; Larsson Rolf; Nygren Peter; Kristensen Jörgen; Sundström Christer; Höglund Martin
In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin's lymphoma.
British journal of haematology 2002;117(3):563-8.
2002: Svensson Asa; Bäckman Ulrika; Jonsson Elin; Larsson Rolf; Christofferson Rolf
CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs.
Pediatric research 2002;51(5):607-11.
2002: Lindholm Petra; Göransson Ulf; Johansson Senia; Claeson Per; Gullbo Joachim; Larsson Rolf; Bohlin Lars; Backlund Anders
Cyclotides: a novel type of cytotoxic agents.
Molecular cancer therapeutics 2002;1(6):365-9.
2002: Lövborg Henrik; Martinsson Petra; Gullbo Joachim; Ekelund Sara; Nygren Peter; Larsson Rolf
Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells.
Biochemical pharmacology 2002;63(8):1491-8.
2002: Ohman Linda; Gedda Lars; Hesselager Göran; Larsson Rolf; Nister Monica; Stigbrand Torgny; Wester Kenneth; Carlsson Jörgen
A new antibody recognizing the vIII mutation of human epidermal growth factor receptor.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2002;23(2):61-9.
2002: Berglund Ake; Glimelius Bengt; Bergh Jonas; Brodin Ola; Fjällskog Marie-Louise; Hagberg Hans; von Heideman Anne; Larsson Rolf; Tholander Bengt; de la Torre Manuel; Aström Gunnar; Oberg Kjell; Parö Gunnar; Nygren Peter
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.
Medical oncology (Northwood, London, England) 2002;19(3):151-9.
2001: Hassan S B; Jonsson E; Larsson R; Karlsson M O
Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action.
The Journal of pharmacology and experimental therapeutics 2001;299(3):1140-7.
2001: Aleskog A; Bashir-Hassan S; Hovstadius P; Kristensen J; Höglund M; Tholander B; Binderup L; Larsson R; Jonsson E
Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro.
Anti-cancer drugs 2001;12(10):821-7.
2001: Martinsson P; Liminga G; Nygren P; Larsson R
Characteristics of etoposide-induced apoptotic cell death in the U-937 human lymphoma cell line.
Anti-cancer drugs 2001;12(8):699-705.
2001: Bennet W; Sundberg B; Elgue G; Larsson R; Korsgren O; Nilsson B
A new in vitro model for the study of pig-to-human vascular hyperacute rejection.
Xenotransplantation 2001;8(3):176-84.
2001: Johansson S; Lindholm P; Gullbo J; Larsson R; Bohlin L; Claeson P
Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells.
Anti-cancer drugs 2001;12(5):475-83.
2001: Ekelund S; Nygren P; Larsson R
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.
Biochemical pharmacology 2001;61(10):1183-93.
2001: Ekelund S; Sjöholm A; Nygren P; Binderup L; Larsson R
Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS 828. Comparison with methylglyoxal-bis(guanylhydrazone).
European journal of pharmacology 2001;418(1-2):39-45.
2001: Martinsson P; de la Torre M; Binderup L; Nygren P; Larsson R
Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells.
European journal of pharmacology 2001;417(3):181-7.
2001: Hassan S B; de la Torre M; Nygren P; Karlsson M O; Larsson R; Jonsson E
A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828.
Anti-cancer drugs 2001;12(1):33-42.
2001: Martinsson P; Liminga G; Dhar S; de la Torre M; Lukinius A; Jonsson E; Bashir Hassan S; Binderup L; Kristensen J; Larsson R
Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells.
European journal of cancer (Oxford, England : 1990) 2001;37(2):260-7.
2001: Jonsson E; Friberg L E; Karlsson M O; Hassan S B; Nygren P; Kristensen J; Tholander B; Binderup L; Larsson R
In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients.
Cancer letters 2001;162(2):193-200.
2000: Liminga G; Martinsson P; Jonsson B; Nygren P; Larsson R
Apoptosis induced by calcein acetoxymethyl ester in the human histiocytic lymphoma cell line U-937 GTB.
Biochemical pharmacology 2000;60(12):1751-9.
2000: von Heideman A; Sandström M; Csoka K; Tholander B; Larsson R; Bergh J; Nygren P
Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(10):1301-7.
2000: Jonsson E; Dhar S; Jonsson B; Nygren P; Graf W; Larsson R
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
European journal of cancer (Oxford, England : 1990) 2000;36(16):2120-7.
2000: Ekelund S; Liminga G; Björkling F; Ottosen E; Schou C; Binderup L; Larsson R
Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: comparison with m-iodobenzylguanidine.
Biochemical pharmacology 2000;60(6):839-49.
2000: Bennet W; Sundberg B; Song Z; Elgue G; Wennberg L; Richards A; White D J; Larsson R; Nilsson B; Groth C; Korsgren O
Porcine islets of langerhans isolated from normal and hDAF transgenic pigs elicit the same acute inflammatory reaction during exposure to human blood; inhibition of the response with soluble complement receptor 1 and heparin.
Transplantation proceedings 2000;32(5):1065.
2000: Dhar S; Gullbo J; Csoka K; Eriksson E; Nilsson K; Nickel P; Larsson R; Nygren P
Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients.
European journal of cancer (Oxford, England : 1990) 2000;36(6):803-9.
2000: Bennet W; Sundberg B; Lundgren T; Tibell A; Groth C G; Richards A; White D J; Elgue G; Larsson R; Nilsson B; Korsgren O
Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin.
Transplantation 2000;69(5):711-9.
2000: Jonsson E; Friberg L E; Karlsson M O; Hassan S B; Freijs A; Hansen K; Larsson R
Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats.
Cancer chemotherapy and pharmacology 2000;46(6):493-500.
2000: Bennet W; Groth C G; Larsson R; Nilsson B; Korsgren O
Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes.
Upsala journal of medical sciences 2000;105(2):125-33.
1999: Liminga G; Jonsson B; Nygren P; Larsson R
On the mechanism underlying calcein-induced cytotoxicity.
European journal of pharmacology 1999;383(3):321-9.
1999: Bennet W; Sundberg B; Groth C G; Brendel M D; Brandhorst D; Brandhorst H; Bretzel R G; Elgue G; Larsson R; Nilsson B; Korsgren O
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation?
Diabetes 1999;48(10):1907-14.
1999: Karlsson M O; Molnar V; Freijs A; Nygren P; Bergh J; Larsson R
Pharmacokinetic models for the saturable distribution of paclitaxel.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(10):1220-3.
1999: Zhou R; Wang Y; Gruber A; Larsson R; Castaños-Vèlez E; Liliemark E
Topoisomerase II-mediated alterations of K562 drug resistant sublines.
Medical oncology (Northwood, London, England) 1999;16(3):191-8.
1999: Aleskog A; Larsson R; Höglund M; Sundström C; Kristensen J
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA.
European journal of haematology 1999;62(5):293-9.
1999: Fridborg H; Jonsson E; Nygren P; Larsson R
Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic.
European journal of cancer (Oxford, England : 1990) 1999;35(3):424-32.
1998: Jonsson E; Fridborg H; Nygren P; Larsson R
Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.
European journal of clinical pharmacology 1998;54(7):509-14.
1998: Larsson R; Dhar S; Ehrsson H; Nygren P; Lewensohn R
Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.
British journal of cancer 1998;78(3):328-35.
1998: Ekelund S; Nygren P; Larsson R
Microphysiometry: new technology for evaluation of anticancer drug activity in human tumor cells in vitro.
Anti-cancer drugs 1998;9(6):531-8.
1998: Dhar S; Nygren P; Liminga G; Sundström C; de la Torre M; Nilsson K; Larsson R
Relationship between cytotoxic drug response patterns and activity of drug efflux transporters mediating multidrug resistance.
European journal of pharmacology 1998;346(2-3):315-22.
1998: Karlsson M O; Molnar V; Bergh J; Freijs A; Larsson R
A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
Clinical pharmacology and therapeutics 1998;63(1):11-25.
1997: Csóka K; Tholander B; Gerdin E; de la Torre M; Larsson R; Nygren P
In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).
International journal of cancer. Journal international du cancer 1997;72(6):1008-12.
1997: Csóka K; Dhar S; Fridborg H; Larsson R; Nygren P
Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro.
Cancer 1997;79(6):1225-33.
1997: Jonsson K B; Frost A; Larsson R; Ljunghall S; Ljunggren O
A new fluorometric assay for determination of osteoblastic proliferation: effects of glucocorticoids and insulin-like growth factor-I.
Calcified tissue international 1997;60(1):30-6.
1997: Jonsson E; Fridborg H; Csóka K; Dhar S; Sundström C; Nygren P; Larsson R
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
British journal of cancer 1997;76(2):211-9.
1997: Martinsson P; Nygren P; Fridborg H; Nilsson K; Kristensen J; Larsson R
Cytotoxic activity of cyclosporin A and [3-keto-Bmt1]-[Val2]-cyclosporin (SDZ PSC 833) on tumour cells from patients with haematological malignancies.
European journal of clinical pharmacology 1997;52(3):199-203.
1996: Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Journal of experimental therapeutics & oncology 1996;1(5):286-95.
1996: Dhar S; Nygren P; Csoka K; Botling J; Nilsson K; Larsson R
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
British journal of cancer 1996;74(6):888-96.
1996: Ridefelt P; Larsson R; Nygren P; Larsson E; Nilsson K
Modulation of calcium signalling and proliferation in monoblastoid U-937 cells.
Anticancer research 1996;16(4A):1643-50.
1996: Jonsson B; Liminga G; Csoka K; Fridborg H; Dhar S; Nygren P; Larsson R
Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours.
European journal of cancer (Oxford, England : 1990) 1996;32A(5):883-7.
1996: Sandström M; Freijs A; Larsson R; Nygren P; Fjällskog M L; Bergh J; Karlsson M O
Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1581-8.
1996: Fridborg H; Nygren N; Larsson R
Correlation between sensitivity in vitro of patient chronic lymphocytic leukemia cells and clinical systemic exposure at the maximum tolerated dose for cell cycle phase-specific (type 2) anticancer drugs.
Anti-cancer drugs 1996;7(1):105-8.
1995: Csoka K; Nygren P; Graf W; Påhlman L; Glimelius B; Larsson R
Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients.
International journal of cancer. Journal international du cancer 1995;63(3):356-60.
1995: Liminga G; Nygren P; Dhar S; Nilsson K; Larsson R
Cytotoxic effect of calcein acetoxymethyl ester on human tumor cell lines: drug delivery by intracellular trapping.
Anti-cancer drugs 1995;6(4):578-85.
1995: Csoka K; Liliemark J; Larsson R; Nygren P
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Seminars in oncology 1995;22(4 Suppl 11):47-53.
1995: Fridborg H; Nygren P; Larsson R
Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs.
Anti-cancer drugs 1995;6(1):64-9.
1994: Larsson R; Nygren P
Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors.
Cancer 1994;74(10):2857-62.
1994: Kristensen J; Nygren P; Liliemark J; Fridborg H; Killander A; Simonsson B; Oberg G; Larsson R
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(10):1712-7.
1994: Holmberg M; Sandberg C; Nygren P; Larsson R
Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein.
Anti-cancer drugs 1994;5(5):598-600.
1994: Csoka K; Larsson R; Tholander B; Gerdin E; de la Torre M; Nygren P
Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).
Gynecologic oncology 1994;54(2):163-70.
1994: Botling J; Liminga G; Larsson R; Nygren P; Nilsson K
Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein.
International journal of cancer. Journal international du cancer 1994;58(2):269-74.
1994: Liminga G; Nygren P; Larsson R
Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833.
Experimental cell research 1994;212(2):291-6.
1994: Fridborg H; Larsson R; Juhlin C; Rastad J; Akerström G; Backlin K; Nygren P
P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells.
Anticancer research 1994;14(3A):1009-16.
1994: Nygren P; Hagberg H; Glimelius B; Sundström C; Kristensen J; Christiansen I; Larsson R
In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 1():127-31.
1994: Larsson R; Fridborg H; Liliemark J; Csoka K; Kristensen J; de la Torre M; Nygren P
In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours.
European journal of cancer (Oxford, England : 1990) 1994;30A(7):1022-6.
1993: Larsson R; Nygren P
Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model.
Anticancer research 1993;13(5C):1825-9.
1993: Larsson R; Fridborg H; Kristensen J; Sundström C; Nygren P
In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA).
British journal of cancer 1993;67(5):969-74.
1993: Larsson R; Nygren P
Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1208-12.
1992: Larsson R; Jonsson B; Csoka K; Kristensen J; Nilsson K; Nygren P
Selective cytotoxic activity of cyclosporins against tumor cells from patients with B cell chronic lymphocytic leukemia.
European journal of pharmacology 1992;228(4):237-40.
1992: Jonsson B; Nilsson K; Nygren P; Larsson R
SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Anti-cancer drugs 1992;3(6):641-6.
1992: Nygren P; Kristensen J; Jonsson B; Sundström C; Lönnerholm G; Kreuger A; Larsson R
Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(11):1121-8.
1992: Ridefelt P; Hellman P; Rastad J; Larsson R; Akerström G; Gylfe E
Fluoride interactions with stimulus-secretion coupling of normal and pathological parathyroid cells.
Acta physiologica Scandinavica 1992;145(3):275-85.
1992: Ridefelt P; Nygren P; Hellman P; Larsson R; Rastad J; Akerström G; Gylfe E
Regulation of parathyroid hormone release in normal and pathological parathyroid cells exposed to modulators of protein kinase C.
Acta endocrinologica 1992;126(6):505-9.
1992: Larsson R; Kristensen J; Sandberg C; Nygren P
Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA).
International journal of cancer. Journal international du cancer 1992;50(2):177-85.
1992: Kristensen J; Jonsson B; Sundström C; Nygren P; Larsson R
In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia.
Medical oncology and tumor pharmacotherapy 1992;9(2):65-74.
1991: Nygren P; Larsson R; Gruber A; Peterson C; Bergh J
Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.
British journal of cancer 1991;64(6):1011-8.
1991: Nygren P; Larsson R
Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators.
International journal of cancer. Journal international du cancer 1991;48(4):598-604.
1991: Larsson R; Bergh J; Nygren P
Combination of cyclosporin A and buthionine sulfoximine (BSO) as a pharmacological strategy for circumvention of multidrug resistance in small cell lung cancer cell lines selected for resistance to doxorubicin.
Anticancer research 1991;11(1):455-9.
1991: Joborn H; Larsson R; Rastad J; Nygren P; Akerström G; Ljunghall S
Vasoactive intestinal polypeptide stimulates parathyroid hormone release by interaction with cyclic adenosine monophosphate production of bovine parathyroid cells.
Acta endocrinologica 1991;124(1):54-9.
1990: Larsson R; Nygren P
Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein.
Cancer letters 1990;54(3):125-31.
1990: Larsson R; Nygren P; Ekberg M; Slater L
Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(8):567-71.
1990: Larsson R; Nygren P
Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells.
International journal of cancer. Journal international du cancer 1990;46(1):67-72.
1990: Nygren P; Larsson R
Modulation of vincristine sensitivity of human kidney tumor cells by pharmacological agents interfering with intracellular signals. No apparent relationship to changes in cytoplasmic Ca2+ or pH.
Biochimica et biophysica acta 1990;1052(3):392-8.
1990: Nygren P; Larsson R
Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration.
Bioscience reports 1990;10(2):231-7.
1989: Larsson R; Nygren P
A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture.
Anticancer research 1989;9(4):1111-9.
1989: Larsson R; Nygren P; Forsbeck K; Gylfe E; Nilsson K
Early ionic events associated with phorbol ester induced differentiation and inhibition of cell growth in hematopoietic tumor cell lines.
Anticancer research 1989;9(1):1-7.
1988: Nygren P; Larsson R; Lindh E; Rastad J; Akerström G; Gylfe E
Dimethyl sulfoxide inhibits proliferation but not hypertrophy and functional dedifferentiation of bovine parathyroid cells in culture.
Research communications in chemical pathology and pharmacology 1988;62(2):161-71.
1988: Nygren P; Larsson R; Johansson H; Ljunghall S; Rastad J; Akerström G
1,25(OH)2D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells.
Calcified tissue international 1988;43(4):213-8.
1988: Johansson H; Larsson R; Wallfelt C; Rastad J; Akerström G; Gylfe E
Calcium-agonistic action of Mn2+ in the parathyroid cell.
Molecular and cellular endocrinology 1988;59(1-2):77-82.
1988: Forsbeck K; Nilsson K; Nygren P; Larsson R; Gylfe E; Skoglund G; Ingelman-Sundberg M
Phorbol-ester-induced stable changes in the regulation of DNA synthesis and intracellular pH are accompanied by altered expression of protein kinase C in the monoblastoid cell line U-937.
International journal of cancer. Journal international du cancer 1988;42(2):284-8.
1988: Nygren P; Larsson R; Johansson H; Gylfe E; Rastad J; Akerström G
Inhibition of cell growth retains differentiated function of bovine parathyroid cells in monolayer culture.
Bone and mineral 1988;4(2):123-32.
1988: Wallfelt C; Lindh E; Larsson R; Johansson H; Rastad J; Akerström G; Gylfe E
Kinetic evidence for cytoplasmic calcium as an inhibitory messenger in parathyroid hormone release.
Biochimica et biophysica acta 1988;969(3):257-62.
1988: Forsbeck K; Nygren P; Larsson R; Nilsson M; Nilsson K; Gylfe E
Cytoplasmic pH is differently regulated in the monoblastic U-937 and erythroleukemic K-562 cell lines.
Experimental cell research 1988;176(1):96-106.
1988: Wallfelt C; Gylfe E; Larsson R; Ljunghall S; Rastad J; Akerström G
Relationship between external and cytoplasmic calcium concentrations, parathyroid hormone release and weight of parathyroid glands in human hyperparathyroidism.
The Journal of endocrinology 1988;116(3):457-64.
1988: Nygren P; Gylfe E; Larsson R; Johansson H; Juhlin C; Klareskoq L; Akerström G; Rastad J
Modulation of the Ca2+-sensing function of parathyroid cells in vitro and in hyperparathyroidism.
Biochimica et biophysica acta 1988;968(2):253-60.
1987: Johansson H; Larsson R; Nygren P; Lindh E; Rastad J; Akerström G; Gylfe E
Cytoplasmic Ca2+ concentration of single normal human and bovine parathyroid cells measured by dual wavelength microfluorometry.
Bioscience reports 1987;7(9):705-12.
1987: Nygren P; Larsson R; Forsbeck K; Nilsson K; Gylfe E
TPA induces cytoplasmic alkalinization in human monoblastic U-937 cells without activation of Na+/H+ exchange.
Experimental cell research 1987;171(1):265-9.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Rolf Larsson

Research Profile (preview)

Anatomy

Chemicals & Drugs

Procedures

Physiology

Concepts & Ideas

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Rolf Larsson (preview)

All Publications